Health Trials

Neuroectodermal Tumors Primitive

2

Review clinical trials related to Neuroectodermal Tumors Primitive. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD

Participants needed: 24
Trial details
Phase: Phase 1Age: 3-21Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: May 15, 2026Locations: 3
Eligibility criteria

Age ≥ 36 months and < 22 years [+12]

Any treatment outside the allowable guidelines outlined in section 5.1. [+10]

Read more
Status: Recruiting

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DLTs) following single weekly or multiple-day weekly dose regimens of single-agent, oral ONC206 in patients with recurrent, primary central nervous system (CNS) neoplasms.

Participants needed: 102
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Jazz PharmaceuticalsUpdated: Dec 18, 2025Locations: 1
Eligibility criteria

Patients aged ≥18 years with a recurrent, primary CNS neoplasm. For all cohorts,... [+21]

(Exclusion Criterion #1 was removed in Amendment 3) [+33]

Read more